In gefitinib-resistant NSCLC cells, inhibition of STAT3 reduces PDL1 expression [299], and enhances the efficacy of anti-PD1/PDL1 immunotherapies in NSCLC tumor-bearing mice [81]. The gene discussed is STAT3; the disease is neoplasm.